TB-500: research overview

The short version

TB-500 is a small, lab-made peptide — seven amino acids long — that corresponds to a short piece of a much larger natural protein called thymosin beta-4. That larger protein helps cells move and helps new blood vessels form, which is part of how injured tissue rebuilds itself. The idea behind TB-500 is that this small fragment might carry some of the same activity in a form that is easier and cheaper to manufacture.

There is an important catch: almost all of the encouraging research is on the full-length protein, not on the short fragment actually sold as TB-500 ^[1]. Human safety testing exists for the full-length protein at fairly high doses ^[4], but there is no completed controlled human trial of the fragment itself, for any use. This page separates what has been shown for each form, reports community accounts honestly as anecdotes, and does not suggest a dose for a person.

What it is

TB-500 is the trade name for a synthetic, N-acetylated seven-amino-acid peptide (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, or Ac-LKKTETQ), corresponding to residues 17-23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein encoded by the TMSB4X gene. That LKKTETQ stretch is the conserved actin-binding motif shared across the beta-thymosin family.

The identity distinction matters throughout the TB-500 literature: most published efficacy research — the animal wound-healing, stroke and cardiac-repair studies — used the full-length, roughly 4,963-dalton Tβ4 protein, not the roughly 889-dalton seven-amino-acid fragment sold commercially as TB-500. Whether the isolated fragment reproduces the parent protein's effects at typical research doses has not been established in a controlled trial ^[1][3].

How it works

The proposed mechanism starts with actin, a protein that forms part of the cell's internal scaffolding. Full-length thymosin beta-4 is the major intracellular protein that buffers monomeric (unpolymerized) actin, binding it 1:1 and capping both ends of the molecule so it cannot assemble into filaments until needed — a role confirmed by X-ray crystallography of a thymosin-beta-4:actin complex ^[5]. Because actin dynamics drive how cells crawl and migrate, this buffering role is linked in the literature to faster cell movement, new blood-vessel formation (angiogenesis), reduced scar-forming myofibroblast activity, and anti-inflammatory and anti-apoptotic signaling after injury ^[3].

A broad review describes thymosin beta-4 as being released by platelets and macrophages at injury sites, where it is proposed to limit programmed cell death, dampen inflammation and support the growth of new blood supply — the basis for clinical interest in dermal wounds, corneal injury, and heart and nervous-system repair ^[3]. The LKKTETQ fragment carries the actin-binding motif responsible for this mechanism, but whether it reproduces the parent protein's full range of downstream effects at the doses typically used in research settings remains unconfirmed.

What the research shows

A 2026 narrative review of approved and unapproved peptide therapies for musculoskeletal injuries — which lists TB-500/thymosin beta-4 alongside BPC-157 — concludes that many unapproved peptides produce favorable tissue-repair outcomes in animal models, but that rigorous human safety data remain scarce, that there is potential for serious harm, and that these compounds largely operate outside regulatory oversight ^[1].

In a rat model of stroke, intraperitoneal thymosin beta-4 given starting 24 hours after an induced blockage and then every three days for four more doses improved neurological function at 2 and 12 mg/kg body weight — significant from day 14 through day 56 — while 18 mg/kg produced no measurable benefit, a non-monotonic dose-response pattern that a modeled optimal dose of roughly 3.75 mg/kg was proposed to explain ^[2]. A review of the broader field describes thymosin beta-4 as decreasing myofibroblast counts (reducing scar formation) and promoting angiogenesis, forming the rationale behind clinical trials in dermal wounds, corneal injury, and heart and CNS repair ^[3].

The one completed human trial in this space is a Phase 1 study, not an efficacy trial: a randomized, placebo-controlled study gave synthetic thymosin beta-4 intravenously to 40 healthy volunteers across four dose cohorts — a single dose, then daily dosing for 14 days at 42, 140, 420 or 1,260 mg. The peptide was well tolerated, with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, and dose-proportional pharmacokinetics with half-life increasing at higher doses ^[4]. That trial used the full-length protein intravenously, not the injected fragment as typically supplied to researchers.

Reported effects, cautions & safety

Community accounts of TB-500 are widespread online, but they are anecdotal, not clinical evidence — self-reported, untested, and never attached to a verified dose here. The most frequently described benefit is faster-feeling recovery from tendon, ligament and muscle injuries, with some describing less joint pain, stiffness and better range of motion after several weeks, and a smaller number mentioning better wound healing or a general sense of reduced soreness. On the adverse side, mild redness or swelling at the injection site is the most commonly described complaint, followed by temporary tiredness in the first day or two; head rush, brief flu-like feelings and nausea are described less often. These reports vary widely from person to person and are not backed by a controlled study of the fragment.

Several cautions come directly from the peer-reviewed literature rather than from community reports. Human safety data for the fragment itself are essentially absent — the 2026 review notes scarce human safety data and real potential for serious harm across this class of unapproved peptides ^[1]. Thymosin beta-4 is overexpressed in several cancers and linked to tumor spread and to the growth of new blood vessels that feed tumors, so a theoretical cancer concern is taken seriously even though it has not been directly measured for the fragment ^[1]. TB-500 is prohibited by the World Anti-Doping Agency, and anti-doping laboratories have developed detection methods for it and its breakdown products, making it off-limits for tested athletes regardless of any claimed recovery benefit ^[1][4]. An honest counterpoint from the animal literature: in dystrophin-deficient mice, long-term thymosin beta-4 increased the number of regenerating muscle fibers but did not improve muscle strength, heart function or fibrosis — more regeneration on paper did not translate into better function, a caution against assuming felt improvements always mean real structural repair ^[1]. And because material sold as TB-500 is not made to medicine-grade standards, purity and identity can vary between suppliers, which adds an unpredictable variable on top of the biology itself.

Where it fits in recovery & tissue repair

TB-500 anchors the actin-binding, migration-and-angiogenesis side of the recovery-and-repair picture on this desk. It is the compound most associated with tendon, ligament and connective-tissue narratives specifically, complementing KPV's gut-and-inflammation focus and forming two of the four components inside the KLOW blend. Read the comparison page for how the identity, evidence base and cautions for all three line up side by side.